A recent study reveals that people who come off new GLP-1 drugs like Wegovy and Mounjaro may regain shed pounds at a significantly accelerated pace than those who halt traditional lifestyle programs.
Research printed in a major health publication shows that while obese individuals can lose a large proportion of their body weight while using the jabs, the weight returns at an estimated rate of 0.8 kg per month once they quit.
"People using such treatments need to be cognizant of the risk of fast rebound weight gain when the treatment concludes," cautioned expert Dr. Susan Jebb.
This pace of recovery means a reversion to original mass in about 18 months.
Analyzing Treatments
The analysis, which examined dozens of trials involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with older methods.
Scientists point out that people who shed pounds through dieting typically have a less rapid creep back—around 0.1 kg a month—after stopping.
Understanding the Quick Regain
Experts propose the mode of action of the jabs explains the amplified rebound.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Artificially providing GLP-1 concentrations far above than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this GLP-1 'fix' means appetite is uncontrolled, making binge eating far more likely."
A Chronic Condition?
Health authorities advise the jabs for people with weight-linked health risks, alongside recommended diet and exercise modifications.
Many experts say that, given the high risk of relapse, the therapy might need to be long-term.
This opinion is supported by drug manufacturers, who note that the findings "emphasize the long-term nature of excess weight," akin to managing diseases like high blood pressure.
Patient Accounts
Users who have discontinued the jabs explain a powerful resurgence of appetite.
"It was like something flipping and you're instantly extremely hungry," recalled a patient.
This difficulty is worsened if patients have not adopted permanent dietary or behavioural modifications during treatment.
Widespread Adoption
Recent estimates suggest that millions of people in the UK have tried these injections in the past year, with desire continuing to grow.
- Use is more common among females compared to men.
- The middle-aged age group shows the highest level of interest.
- Many obtain the medications through private prescriptions rather than public health services.
Finally, clinicians emphasize that while these medications are effective tools for shedding pounds, they are not a standalone solution and lasting health benefits likely depends on integrated behavioural support.
